For CVS, Q2 earnings will be a critical inflection point. A miss could trigger a breakup or further decline, making the stock ...

Discover Johnson & Johnson's Q2 2025 earnings insights with raised guidance and strategic growth in Oncology & MedTech.

The global study, “The Cost of Silence,” found that companies with an environmental focus grew EBITDA 6% better than ...

Orum Capital, a Los Angeles-based real estate firm that acted through an affiliate, bought the retail site from Longs Drug ...

The contract, though sizable, is likely immaterial to CVS’ earnings. But it moves the company in a positive direction as it ...

CVS Health (CVS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...